small molecule

XENLETA

LEFAMULIN ACETATE

Loss of exclusivityJune 2036latest FDA-listed patent expiry

CompanyHONG KONG KING FRIEND INDUSTRIAL CO LTD

Drug detail

Brand name	XENLETA
Active ingredient	LEFAMULIN ACETATE
Strength	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)
Dosage form	SOLUTION
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	August 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
12121582	June 2036	product
8071643	March 2033	substance, product
8153689	March 2028	substance, product

Regulatory exclusivity

Code	Expires
GAIN	August 2029
NCE	August 2024

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from HONG KONG KING FRIEND INDUSTRIAL CO LTD